Von Willebrand factor and endothelial damage: a possible association with COVID-19

Cover Page

Cite item

Full Text

Abstract

COVID-19 caused by the SARS-CoV-2 virus is a new type of infection which has caused an enormous social and economic burden across the world. While most people will develop a mild-to-moderate form of the disease or even stay asymptomatic, a certain proportion will get critically ill. COVID-19 mortality risk is higher in elderly patients and in patients with cardiovascular diseases and diabetes. Molecular mechanisms which underlie these risks are not yet understood for COVID-19. Here I discuss a possible association of COVID-19 complications with von Willebrand factor (VWF) level and endothelial damage. VFW is an important prognostic marker of endothelial dysfunction and its level fluctuates depending on age. VWF level is also variable depending on sex and race. Importantly, chloroquine, a drug that showed potential efficacy for COVID-19 treatment, can influence VWF secretion and consequently its level and activity. I propose that VWF level and activity might be predictors of the COVID-19 morbidity and mortality; moreover the VWF might be involved in the pathogenesis of the disease. I suggest that a comprehensive study of VWF level in SARS-CoV-2 positive groups of people with mild and severe course of the disease should be undertaken.

About the authors

Anna Yu. Aksenova

Saint Petersburg State University

Author for correspondence.
Email: aksena@gmail.com
ORCID iD: 0000-0002-1601-1615
SPIN-code: 4914-7675
Scopus Author ID: 7004702797
ResearcherId: O-8309-2015

Candidate of Biological Sciences, Senior Researcher

Russian Federation, Saint Petersburg

References

  1. Huang I, Lim MA, Pranata R. Diabetes mellitus is associated with increased mortality and severity of disease in COVID-19 pneumonia – A systematic review, meta-analysis, and meta-regression. Diabetes Metab Syndr. 2020;14(4):395-403. https://doi.org/10.1016/j.dsx.2020.04.018.
  2. Adams ML, Katz DL, Grandpre J. Population-Based Estimates of Chronic Conditions Affecting Risk for Complications from Coronavirus Disease, United States. Emerg Infect Dis. 2020;26(8). https://doi.org/10.3201/eid2608.200679.
  3. La Vignera S, Cannarella R, Condorelli RA, et al. Sex-Specific SARS-CoV-2 Mortality: Among Hormone-Modulated ACE2 Expression, Risk of Venous Thromboembolism and Hypovitaminosis D. Int J Mol Sci. 2020;21(8). https://doi.org/10.3390/ijms21082948.
  4. Yancy CW. COVID-19 and African Americans. JAMA. 2020. https://doi.org/10.1001/jama.2020. 6548.
  5. Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395(10223):497-506. https://doi.org/10.1016/s0140-6736(20)30183-5.
  6. Obe BH, Retter A, Mcclintock C. Practical guidance for the prevention of thrombosis and management of coagulopathy and disseminated intravascular coagulation of patients infected with COVID-19. 2020.
  7. Tang N, Bai H, Chen X, et al. Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy. J Thromb Haemost. 2020;18(5): 1094-1099. https://doi.org/10.1111/jth.14817.
  8. Han H, Yang L, Liu R, et al. Prominent changes in blood coagulation of patients with SARS-CoV-2 infection. Clin Chem Lab Med. 2020. https://doi.org/10.1515/cclm-2020-0188.
  9. Li T, Lu H, Zhang W. Clinical observation and management of COVID-19 patients. Emerg Microbes Infect. 2020;9(1):687-690. https://doi.org/10.1080/ 22221751.2020.1741327.
  10. Lillicrap D. Disseminated intravascular coagulation in patients with 2019-nCoV pneumonia. J Thromb Haemost. 2020;18(4):786-787. https://doi.org/10.1111/jth.14781.
  11. Liu X, Li Z, Liu S, et al. Potential therapeutic effects of dipyridamole in the severely ill patients with COVID-19. Acta Pharm Sin B. 2020. https://doi.org/10.1016/j.apsb.2020.04.008.
  12. Kawecki C, Lenting PJ, Denis CV. von Willebrand factor and inflammation. J Thromb Haemost. 2017;15(7):1285-1294. https://doi.org/10.1111/jth.13696.
  13. Ware LB, Eisner MD, Thompson BT, et al. Significance of von Willebrand factor in septic and nonseptic patients with acute lung injury. Am J Respir Crit Care Med. 2004;170(7):766-772. https://doi.org/10.1164/rccm.200310-1434OC.
  14. El Wahsh R, Amin S, Essa E. Diagnostic value of von Willebrand factor (VWF) in patients suffering from respiratory distress. Eur Respir J. 2011;38:1686.
  15. Torisu T, Torisu K, Lee IH, et al. Autophagy regulates endothelial cell processing, maturation and secretion of von Willebrand factor. Nat Med. 2013;19(10):1281-1287. https://doi.org/10.1038/nm.3288.
  16. Mauthe M, Orhon I, Rocchi C, et al. Chloroquine inhibits autophagic flux by decreasing autophagosome-lysosome fusion. Autophagy. 2018;14(8):1435-1455. https://doi.org/10.1080/15548627.2018.1474314.
  17. Lovren F, Pan Y, Quan A, et al. Angiotensin converting enzyme-2 confers endothelial protection and attenuates atherosclerosis. Am J Physiol Heart Circ Physiol. 2008;295(4): H1377-1384. https://doi.org/10.1152/ajpheart.00331.2008.
  18. Kuba K, Imai Y, Rao S, et al. A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus-induced lung injury. Nat Med. 2005;11(8): 875-879. https://doi.org/10.1038/nm1267.
  19. Imai Y, Kuba K, Rao S, et al. Angiotensin-converting enzyme 2 protects from severe acute lung failure. Nature. 2005;436(7047):112-116. https://doi.org/10.1038/nature03712.
  20. Zhang H, Penninger JM, Li Y, et al. Angiotensin-converting enzyme 2 (ACE2) as a SARS-CoV-2 receptor: molecular mechanisms and potential therapeutic target. Intensive Care Med. 2020;46(4):586-590. https://doi.org/10.1007/s00134-020-05985-9.
  21. Tignanelli CJ, Ingraham NE, Sparks MA, et al. Antihypertensive drugs and risk of COVID-19? Lancet Respir Med. 2020;8(5): e30-e31. https://doi.org/10.1016/s2213-2600(20)30153-3.
  22. Sriram K, Insel PA. A hypothesis for pathobiology and treatment of COVID-19: the centrality of ACE1/ACE2 imbalance. Br J Pharmacol. 2020. https://doi.org/10.1111/bph.15082.
  23. Agostini S, Lionetti V. New insights into the non-hemostatic role of von Willebrand factor in endothelial protection. Can J Physiol Pharmacol. 2017;95(10):1183-1189. https://doi.org/10.1139/cjpp-2017-0126.
  24. Dushpanova A, Agostini S, Ciofini E, et al. Gene silencing of endothelial von Willebrand factor attenuates angiotensin II-induced endothelin-1 expression in porcine aortic endothelial cells. Sci Rep. 2016;6:30048. https://doi.org/10.1038/srep30048.
  25. Cha SA, Park BM, Kim SH. Angiotensin-(1-9) ameliorates pulmonary arterial hypertension via angiotensin type II receptor. Korean J Physiol Pharmacol. 2018;22(4):447-456. https://doi.org/10.4196/kjpp.2018.22.4.447.
  26. Panigada M, Bottino N, Tagliabue P, et al. Hypercoagulability of COVID-19 patients in Intensive Care Unit. A Report of Thromboelastography Findings and other Parameters of Hemostasis. J Thromb Haemost. 2020. https://doi.org/10.1111/jth.14850.
  27. Escher R, Breakey N, Lammle B. Severe COVID-19 infection associated with endothelial activation. Thromb Res. 2020;190:62. https://doi.org/10.1016/ j.thromres.2020.04.014.
  28. Zhao J, Yang Y, Huang H, et al. Relationship between the ABO Blood Group and the COVID-19 Susceptibility. MedRxiv. 2020. https://doi.org/10.1101/2020.03.11.20031096.
  29. Swystun LL, Lillicrap D. Genetic regulation of plasma von Willebrand factor levels in health and disease. J Thromb Haemost. 2018;16(12):2375-2390. https://doi.org/10.1111/jth.14304.
  30. Gill JC, Conley SF, Johnson VP, et al. Low VWF levels in children and lack of association with bleeding in children undergoing tonsillectomy. Blood Adv. 2020;4(1):100-105. https://doi.org/10.1182/bloodadvances.2019000992.
  31. Laffan M. Can you grow out of von Willebrand disease? Haemophilia. 2017;23(6):807-809. https://doi.org/10.1111/hae.13325.
  32. Miller CH, Dilley A, Richardson L, et al. Population differences in von Willebrand factor levels affect the diagnosis of von Willebrand disease in African-American women. Am J Hematol. 2001;67(2): 125-129. https://doi.org/10.1002/ajh.1090.
  33. Sarji KE, Graves JM, Colwell JA. Von Willebrand factor activity in normal subjects: Sex difference and variability. Thromb Res. 1975;7(6):885-895. https://doi.org/10.1016/0049-3848(75)90092-4.
  34. Gragnano F, Sperlongano S, Golia E, et al. The Role of von Willebrand Factor in Vascular Inflammation: From Pathogenesis to Targeted Therapy. Mediators Inflamm. 2017;2017:1-13. https://doi.org/10.1155/2017/5620314.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2020 Aksenova A.Y.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.
 


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies